Literature DB >> 3726929

Review of alterations in oral phenytoin bioavailability associated with formulation, antacids, and food.

A T Cacek.   

Abstract

Since 1938, phenytoin has been widely used for the control of seizure disorders. Phenytoin is available from a variety of manufacturers in a variety of dosage forms. Certain physiochemical properties of phenytoin may lead to bioavailability changes. The physiochemical properties exert themselves not only in the presence of other drugs but also during the manufacturing process. Manufacturing processes that may influence phenytoin bioavailability include salt form, particle size, product excipient, and dosage form. Drug influences upon phenytoin bioavailability largely include antacid anions, which may form insoluble complexes. Anions present within the diet may also influence the rate and extent of phenytoin absorption. This article reviews the various influences on phenytoin bioavailability with regard to the manufacturing process, antacid, and food.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3726929     DOI: 10.1097/00007691-198606000-00007

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  4 in total

Review 1.  Therapeutic drug monitoring of phenytoin. Rationale and current status.

Authors:  M Levine; T Chang
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Impact of excipient interactions on drug bioavailability from solid dosage forms.

Authors:  Ravikiran Panakanti; Ajit S Narang
Journal:  Pharm Res       Date:  2012-05-19       Impact factor: 4.200

3.  Phenytoin absorption in volunteers receiving selected enteral feedings.

Authors:  J R Guidry; T F Eastwood; S C Curry
Journal:  West J Med       Date:  1989-06

4.  Effects of concurrent and staggered dosing of semi-solid enteral nutrients on pharmacokinetic behavior of antiepileptic drugs after oral administration in rats.

Authors:  Katsuhito Nagai; Yoshikazu Ryuno; Yoshihito Iwanami; Sachiko Omotani; Shuhei Fukuno; Yasutoshi Hatsuda; Hiroki Konishi; Michiaki Myotoku
Journal:  PLoS One       Date:  2021-11-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.